<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910568</url>
  </required_header>
  <id_info>
    <org_study_id>GO42552</org_study_id>
    <secondary_id>2021-000238-33</secondary_id>
    <nct_id>NCT04910568</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability,&#xD;
      pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab which will be administered to&#xD;
      participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV)&#xD;
      infusion using a modified weekly schedule.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">December 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response/Stringent Complete Response (CR/sCR) Rate</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Very Good Partial Response (VGPR) or Better</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline to disease progression or death from any cause, whichever occurs first (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From first partial response (PR) until disease progression or death from any cause, whichever occurs first (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response (for Participants who Achieve a Response of Partial Response (PR) or Better)</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Best Response (for Participants who Achieve a Response of PR or Better)</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD) Negativity</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up until death from any cause (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Cevostamab at Specified Timepoints</measure>
    <time_frame>From Cycle 1 Day 1 through Cycle 13 Day 1 and at end of study treatment (up to approximately 3 years). Each cycle=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Exposure (Area Under the Concentration-time Curve [AUC]) of Cevostamab</measure>
    <time_frame>From Cycle 1 Day 1 through Cycle 13 Day 1 and at end of study treatment (up to approximately 3 years). Each cycle=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of Cevostamab</measure>
    <time_frame>From Cycle 1 Day 1 through Cycle 13 Day 1 and at end of study treatment (up to approximately 3 years). Each cycle=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Concentration (Cmin) of Cevostamab</measure>
    <time_frame>From Cycle 1 Day 1 through Cycle 13 Day 1 and at end of study treatment (up to approximately 3 years). Each cycle=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of Cevostamab</measure>
    <time_frame>From Cycle 1 Day 1 through Cycle 13 Day 1 and at end of study treatment (up to approximately 3 years). Each cycle=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State of Cevostamab</measure>
    <time_frame>From Cycle 1 Day 1 through Cycle 13 Day 1 and at end of study treatment (up to approximately 3 years). Each cycle=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Anti-drug Antibody (ADAs) Against Cevostamab at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ADAs Against Cevostamab During the Study</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cevostamab Single-Agent Safety Run-In (Arm A1S) and Single-Agent Expansion (Arm A1E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A1S is a safety run-in arm evaluating Cevostamab administered in 28-day cycles on a modified weekly schedule.&#xD;
Upon completion of Arm A1S, Arm A1E, an expansion cohort may be opened. Participants will be treated with single-agent cevostamab administered in 28-day cycles on a modified weekly schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cevostamab</intervention_name>
    <description>Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles.</description>
    <arm_group_label>Cevostamab Single-Agent Safety Run-In (Arm A1S) and Single-Agent Expansion (Arm A1E)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.</description>
    <arm_group_label>Cevostamab Single-Agent Safety Run-In (Arm A1S) and Single-Agent Expansion (Arm A1E)</arm_group_label>
    <other_name>Actemra/RoActemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Diagnosis of R/R MM for which no established therapy for MM is appropriate and&#xD;
             available, or intolerance to those established therapies&#xD;
&#xD;
          -  Agreement to provide bone marrow biopsy and aspirate samples&#xD;
&#xD;
          -  Resolution of adverse events from prior anti-cancer therapy to Grade &lt;=1&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with cevostamab or another agent with the same target&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             3 months after the last dose of study drug&#xD;
&#xD;
          -  Prior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate&#xD;
             as anti-cancer therapy within 4 weeks before first study treatment, except for the use&#xD;
             of non-myeloma therapy&#xD;
&#xD;
          -  Prior treatment with systemic immunotherapeutic agents, including, but not limited to,&#xD;
             cytokine therapy and anti-CTLA4, anti-PD-1, and antiPD-L1 therapeutic antibodies&#xD;
             within 12 weeks or 5 half-lives of the drug, whichever is shorter, before first study&#xD;
             treatment&#xD;
&#xD;
          -  Prior treatment with chimeric antigen receptor T (CAR T)-cell therapy within 12 weeks&#xD;
             before first cevostamab infusion&#xD;
&#xD;
          -  Prior allogeneic stem cell transplant(ation) (SCT)&#xD;
&#xD;
          -  Known treatment-related, immune-mediated adverse events associated with prior&#xD;
             checkpoint inhibitors&#xD;
&#xD;
          -  Current or past history of central nervous system (CNS) disease, such as stroke,&#xD;
             epilepsy, CNS vasculitis, neurodegenerative disease, or CNS involvement by MM&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Symptomatic active pulmonary disease or requiring supplemental oxygen&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection&#xD;
&#xD;
          -  Known or suspected chronic active Epstein-Barr virus (EBV) infection&#xD;
&#xD;
          -  Recent major surgery within 4 weeks prior to first study treatment&#xD;
&#xD;
          -  Positive serologic or PCR test results for acute or chronic hepatitis B virus (HBV)&#xD;
             infection&#xD;
&#xD;
          -  Acute or chronic hepatitis C virus (HCV) infection&#xD;
&#xD;
          -  Known history of HIV seropositivity&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before first study&#xD;
             treatment or anticipation that such a live attenuated vaccine will be required during&#xD;
             the study&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications, with the exception of&#xD;
             corticosteroid treatment &lt;=10 mg/day prednisone or equivalent, within 2 weeks prior to&#xD;
             first study treatment&#xD;
&#xD;
          -  History of illicit drug or alcohol abuse within 12 months prior to screening, in the&#xD;
             investigator's judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO42552 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute.</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre; Department of Haematology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital; Malignant Haematology &amp; Stem Cell Transplant Service</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Health Network; Princess Margaret Hospital; Medical Oncology Dept</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

